Cyclins and CDKS in development and cancer: Lessons from genetically modified mice

Frontiers in Bioscience

Volumn 11, Issue 1 P.889-1198, 2006, Pages 1164-1188

  Santamaria, David ^a   Ortega, Sagrario ^a  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

Cancer; Cdks; Cell Cycle; Cyclins; Gene targeting; Genetically Modified Mouse; Model; Neoplasia; Review; Tumor

Indexed keywords

MAMMALIA;

EID: 27144458683     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/1871     Document Type: Review

References (180)

1. Norbury C & P. Nurse: Animal cell cycles and their control. Annu Rev Biochem 61, 441-70 (1992)
2. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 81: 323-30 (1995)
3. 1 cyclin-dependent kinases. Genes Dev 9, 1149-63 (1995)
4. Sherr CJ: Cancer cell cycles. Science 274, 1672-77 (1996)
5. Murray AW: Recycling the cell cycle: cyclins revisited. Cell 116: 221-234 (2004)5.
6. Sherr CJ & J.M. Roberts: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes & Dev 13, 1501-12 (1999)
7. Morgan DO: Cyclin-dependent kinases: engines, clocks and microprocessors. Annu Rev Cell Dev Biol 13, 261-91 (1997)
8. Lundberg AS, & R.A. Weinberg: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two cyclin-cdk complexes. Mol Cell Biol 18, 753-61 (1998)
9. 0 exit. Cell 117, 239-51 (2004)
10. Ye X, C. Zhu & J.W. Harper: A premature termination mutation in the Mus musculus cyclin dependent kinase 3 gene. Proc Natl Acad Sci USA 98:1682-6 (2001)
11. Malumbres M: Revisiting the "Cdk-centric" view of the mammalian cell cycle. Cell Cycle 4, e19-e23 (2005)
12. Tezlaff MT, C. Bai, M. Finegold, J. Wilson, J.W. Harper, K.A. Mahon & S.J. Elledge: Cyclin F disruption compromises placental development and affects normal cell cycle progression. Mol Cell Biol 24, 2487-98 (2004)
13. Sherr CJ & J.M. Roberts: Living with or without cyclins and cyclin dependent kinases. Genes & Dev 18, 2699-711 (2004)
14. Koepp DM, J.W. Harper & S.J. Elledge: How the cyclin became a cyclin: regulated proteolysis in the cell cycle. Cell 97, 431-4 (1999)
15. Jones SM & A. Kazlauskas: Growth-factor-dependent mitogenesis requires two distinct phases of signalling. Nat Cell Biol 3, 165-72 (2001)
16. Pavletich NP: Mechanisms of cyclin-dependent kinase regulation: structures of cdks, their cyclin activators and Cip and INK inhibitors. J Mol Biol 287, 821-8 (1999)
17. Frolov MV & N.J. Dyson: Molecular mechanisms of E2F-dependent activation and pRB-mediated repression. J Cell Sci 17: 2173-81 (2004)
18. Brehm A & T. Kouzarides: Retinoblastoma protein meets chromatin. Trends Biochem Sci 24, 142-5 (1999)
19. Constanzo M, J.L. Nishikawa, X. Tang, J.S. Millman, O. Schub, K. Breitkreuz, D. Dewar, I. Rupes, B. Andrews & M. Tyers: CDK activity antagonizes Whi5, an inhibitor of G1/S transition in yeast. Cell 117, 849-50 (2004)
20. Pardee AB: A restriction point for control of normal animal cell proliferation. Proc Natl Acad Sci USA 71, 1286-90 (1974)
21. Lukas J, T. Herzinger, K. Hansen, M.C. Moroni, D. Resnitzky, K. Helin, S.I. Reed & J. Bartek: Cyclin E-induced S phase without activation of the pRB/E2F pathway. Genes Dev 11, 1479-92 (1997)
22. Geng Y, W. Whoriskey, M.Y. Park, R.T. Bronson, R.H. Medema, T. Li, R.A. Weinberg & P. Sicinski: Rescue of cyclin D1 deficiency by knockin cyclin E. Cell 97, 767-77 (1999)
23. Geng Y, Q. Yu, E. Sicinska, M. Das, R.T. Bronson & P. Sicinski: Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci USA 98, 194-9 (2001)
24. Cheng M, P. Olivier, J.A. Diehl, M. Fero, M.F. Roussel, J.M. Roberts & C.J. Sherr: The p21Cip1 and p27Kip1 CDK inhibitors are essential activators of cyclin D-dependent kinases in murine fibroblasts. EMBO J 18, 1571-83 (1999)
25. Olashaw N, T.K. Bagui & W.J. Pledger: Cell cycle control: a complex issue. Cell Cycle 3, 263-4 (2004)
26. Bracken AP, M. Ciro, A. Cocito & K. Helin: E2F target genes: unravelling the biology. Trends Biochem Sci 29, 409-17 (2004)
27. Matsuura I, N.G. Denissova, G. Wang, D. He, J. Long & F. Liu: Cyclin-dependent kinases regulate the antiproliferative function of Smads. Nature 430, 226-31 (2004)
28. Coqueret O: Linking cyclins to transcriptional control. Gene 299, 35-55 (2002)
29. Sheaff RJ, M. Groudine, M. Gordon, J.M. Roberts & B.E. Clurman: Cyclin E-CDK2 is a regulator of p27Kip1. Genes Devil, 1464-78 (1997)
30. Vlach J, S. Henneke & B. Amati: Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. EMBO J 16, 5334-44 (1997)
31. Koepp DM, L.K. Schaeffer, X. Ye, K. Keyomarsi, C. Chu, J.W. Harper & S.J. Elledge: Phosphorylation dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science 294, 173-7 (2001)
32. Möröy T, and C. Geisen: Cyclin E. Int J Biochem Cell Biol 36, 1424-39 (2004)
33. Wianny F, F.X. Real, C.L. Mummery, M. Van Rooijen, J. Lahti, J. Samarut & P. Savatier: G1-phase regulators, cyclin D1, cyclin D2 and cyclin D3: up-regulation at gastrulation and dynamic expression during neurulation. Dev. Dyn 212, 49-62 (1998)
34. Fantl V, G. Stamp, A. Andrews, I. Rosewell & C. Dickson: Mice lacking cyclin D1 are small and show defects in eye and mammary gland development. Genes & Dev 9, 2364-72 (1995)
35. Sicinski P, J.L. Donaher, S.B. Parker, H. Gardner, S.Z. Haslam, R.T. Bronson, S.J. Elledge & R.J. Weinberg: Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell 82, 621-30 (1995)
36. Sicinski P, J.L. Donaher, Y. Geng, S.B. Parker, H. Gardner, M.Y. Park, R.L. Robker, J.S. Richards, L.K. McGinnis, J.D. Biggers, J.J. Eppig, R.T. Bronson, S.J. Elledge and R.A. Weinberg: Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature 384, 470-474 (1996)
37. Sicinska E, I. Aifantis, L. Le Cam, W. Swat, C. Borowski, Q. Yu, A.A. Ferrando, S.D. Levin, Y. Geng, H. von Boehmer & P. Sicinski: Requirement for Cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-61 (2003)
38. Ciemerych MA & P. Sicinski: Cell cycle in mouse development. Oncogene 24, 2877-2898 (2005)
39. Pagano M & P.K. Jackson: Wagging the dogma: tissue-specific cell cycle control in the mouse embryo. Cell 118, 535-8 (2004)
40. Ciemerych MA, A.M. Kenney, E. Sicinska, I. Kalaszcynska, R.T. Bronson, D.H. Rowitch, H. Gardner & P. Sicinski: Development of mice expressing a single D-type cyclin. Genes & Dev 16, 3277-89 (2002)
41. Carthon BC, C.A. Neumann, M. Das, B. Pawlik, T. Li, Y. Geng & P. Sicinski: Genetic replacement of Cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol 25, 1081-8 (2005)
42. Rane SG, P. Dubus, R.V. Mettus, E.J. Galbreath, G. Boden, E.P. Reddy & M. Barbacid: Loss of Cdk4 expression causes insulin-deficiente diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet 22, 44-52 (1999)
43. Tsutsui T, B. Hesabi, D.S. Moons, P.P. Pandolfi, K.S. Hansel, A. Koff & H. Kiyokawa: Targeted disruption of Cdk4 delays cell cycle entry with enhanced p27Kip1 activity. Mol Cell Biol 19, 7011-9 (1999)
44. Moons DS, S. Jirawatnotai, A.F. Parlow, G. Gibori, R.D. Kineman & H. Kiyokawa: Pituitary hypoplasia and lactotroph dysfuntcion in mice deficient for cyclin-dependent kinase 4. Endocrinology 143, 3001-8 (2002)
45. Martín J, S. Hunt, P. Dubus, R. Sotillo, F. Néhmé- Pélluard, M.A. Magnuson, A.F. Parlow, M. Malumbres, S. Ortega & M. Barbacid: Genetic rescue of Cdk4 null mice restores pancreatic beta-cell proliferation but not homeostatic cell number. Oncogene 22, 5261-9 (2003)
46. Sotillo R, P. Dubus, J. Martín , E. de la Cueva, S. Ortega, M. Malumbres & M. Barbacid: Wide spectrum of tumors in knockin mice carrying a Cdk4 protein insensitive to INK4 inhibitors. EMBO J 20, 6637-47 (2001)
47. Georgia S & A. Bhushan: Beta cell replication is the primary mechanism for maintaining postnatal beta cell mass. J Clin Invest 114, 963-8 (2004)
48. Kushner JA, M.A. Ciemerych, E. Sicinska, L.M. Wartschow, M. Teta, S.Y. Long, Sicinski, P. & M.F. White: Cyclins D2 and D1 are essential for postnatal pancreatic beta-cell growth. Mol Cell Biol 25, 3752-62 (2005)
49. Meyer CA, H.W. Jacobs & C.F. Lehner: Cyclin D-cdk4 is not a master regulator of cell multiplication in Drosophila embryos. Curr Biol 12, 661-6 (2002)
50. Malumbres M, R. Sotillo, D. Santamaría, J. Galán, A. Cerezo, S. Ortega, P. Dubus & M. Barbacid: Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 118, 493-504 (2004)
51. Kozar K, M. A. Ciemerych, V.I. Rebel, H. Shigematsu, A. Zagozdzon, E. Sicinska, Y. Geng, Q. Yu, S. Bhattacharya, R.T. Bronson, K. Akashi & P. Sicinski: Mouse development and cell proliferation in the absence of D-cyclins. Cell 118, 477-91 (2004)
52. Park I, D. Qian, M. Kiel, M. Becker, M. Pihalja, I. Weissman, S. Morrison & M. Clarke: Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423, 302-5 (2003)
53. Sherr C J: Principles of tumor suppression. Cell 116, 235-46 (2004)
54. Zarkowska T & S. Mittnacht: Differential phosphorylation of the retinoblastoms protein by G1/S cyclin-dependent kinases. J Biol Chem 272, 12738-46 (1997)
55. Ewen ME, B. Faha, E. Harlow & D.M. Livingston: Interaction of p107 with cyclin A independent of complex formation with viral oncoproteins. Science 255, 85-7 (1992)
56. Santoni-Rugiu E, J. Falck, N. Mailand, J. Bartek & J. Lukas: Involvement of Myc activity in a G(1)/S-promoting mechanism parallel to the pRb/E2F pathway. Mol Cell Biol 20, 3497-509 (2000)
57. van den Heuvel SJL & E. Harlow: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262, 2050-4 (1993)
58. Tetsu O & F. McCormick: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 3, 233-45 (2003)
59. Roberts JM & C.J. Sherr: Bared essentials of CDK2 and cyclin E. Nat Genet 35, 9-10 (2003)
60. Ortega S, I. Prieto, J. Odajima, A. Martín, P. Dubus, R. Sotillo, J.L. Barbero, M. Malumbres & M. Barbacid: Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 35, 25-31 (2003)
61. Berthet C, E. Aleem, V. Coppola, L. Tessarollo & P. Kaldis: Cdk2 knockout mice are viable. Curr Biol 13, 1775-85 (2003)
62. Gladden AB & J.A. Diehl: Cell cycle progression without cyclin E/CDK2: breaking down the walls of dogma. Cancer Cell 4, 160-2 (2003)
63. Pacek M, T.A. Prokhorova & J.C. Walter: Cdk1: Unsung hero of S phase?. Cell Cycle 3, 401-3 (2004)
64. Jackman M, C. Lindon, E.A. Nigg & J. Pines: Active cyclin B1-Cdk1 first appears on centrosomes in prophase. Nat Cell Biol 5, 143-8 (2003)
65. Moore JD, J.A. Kirk & T. Hunt: Unmasking the S-phase-promoting potential of cyclin B1. Science 300, 987-90 (2003)
66. Fisher DL & P. Nurse: A single fission yeast mitotic cyclin B-p34cdc2 kinase promotes both S-phase and mitosis in the absence of G1 cyclins. EMBO J 15, 850-60 (1996)
67. Donaldson AD: The yeast mitotic cyclin Clb2 cannot substitute for S phase cyclins in replication origin firing. EMBO Rep 1, 507-12 (2000)
68. Simone C, L. Bagella, C. Bellan & A. Giordano: Physical interaction between pRb and cdk9/cyclin T2 complex. Oncogene 21, 4158-65 (2002)
69. Manning G, G.D. Plowman, T. Hunter & S. Sudarsanam: Evolution of protein kinase signalling from yeast to man. Trends Biochem Sci 27, 514-20.
70. Caenepeel S, G. Charydczak, S. Sudarsanam, T. Hunter & G. Manning: The mouse kinome: discovery and comparative genomics of all mouse protein kinases. Proc Natl Acad Sci USA 101, 11707-12 (2004)
71. Liu D, M.M. Matzuk, W.K. Sung, Q. Guo, P. Wang & D.J. Wolgemuth: Cyclin A1 is required for meiosis in the male mouse. Nat Genet 20, 377-80 (1998)
72. Liu D, C. Liao & D.J. Wolgemuth: A role for Cyclin A1 in the activation of MPF and G2-M transition during meiosis of male germ cells in mice. Dev Biol 224, 388-400 (2000)
73. Müller-Tidow C, P. Ji, S. Diederichs, J. Potrazt, N. Bäumer, G. Kohler, T. Cauvet et al.: The Cyclin A1-CDK2 complex regulates DNA double-strand break repair. Mol Cell Biol 24, 8917-28 (2004)
74. Diederichs S, N. Bäumer, P. Ji, S.K. Metzelder, G.E. Idos, T. Cauvet et al.: Identification of interaction partners and substrates of the Cyclin A1-CDK2 complex. J Biol Chem 279, 33727-41 (2004)
75. Esashi F, N. Christ, J. Gannon, Y. Liu, T. Hunt, M. Jasin & S. West: CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombination and repair. Nature 434, 598-604 (2005)
76. Geng Y, Q. Yu, E. Sicinska, M. Das, J.E. Schneider, S. Bhattacharya, W.M. Rideout III, R.T. Bronson, H. Gardner & P. Sicinski: Cyclin E ablation in the mouse. Cell 114, 431-43 (2003)
77. Parisi T, A.R. Beck, N. Rougier, T. McNeil, L. Lucian, Z. Werb & B. Amati: Cyclins E1 and E2 are required for endoreplication in placental trophoblast giant cells. EMBO 718, 4794-803 (2003)
78. Geng, Y, Q. Yu, W. Worishek, F. Dick, K.Y. Tsai, H.L. Ford, D.K. Biswas, A.B. Pardee, B. Amati, T. Jacks, A, Richardson, N. Dyson & P. Sicinski: Expression of cyclins E1 and E2 during mouse development and in neoplasia. Proc Natl Acad Sci USA 98, 13138-43 (2001)
79. Tanaka M, M. Gertsenstein, J. Rossant, & A. Nagy: Mash2 acts cell autonomously in mouse spongiotrophoblast development. Dev Biol 190, 55-65 (1997)
80. rd Rideout, R. Yanagimachi, & R. Jaenisch: Hybrid vigor, fetal overgrowth, and viability of mice derived by nuclear cloning and tetraploid embryo complementation. Proc Natl Acad Sci USA 98, 6209-6214 (2001)
81. Schwenk F, B. Zevnik, J. Bruning, M. Rohl, A. Willuweit, A. Rode, T. Hennek, G. Kauselmann, R. Jaenisch & R. Kuhn: Hybrid embryonic stem cell-derived tetraploid mice show apparently normal morphological, physiological and neurological characteristics. Mol Biol Cell 23, 3982-9 (2003)
82. Palazón LS, T.J. Davies & R.L. Gardner: Translational inhibition of cyclin B1 and appearance of cyclin D1 very early in the differentiation of mouse trophoblast giant cells. Mol Hum Reprod 4, 1013-20 (1998)
83. Su TT & P.H. O'Farrel: Chromosome association of minichromosome maintenance proteins in Drosophila endoreplicative cycles. J Cell Biol 140, 451-60 (1998)
84. Diffley JF: Regulation of early events in chromosome replication. Curr Biol 21, 778-86 (2004)
85. Harvey KJ & J. Newport: Metazoan origin selection: origin recognition complex chromatin binding is regulated by CDC6 recruitment and ATP hydrolysis. J Biol Chem 278, 48524-8 (2003)
86. Madine MA, M. Swietlik, C. Pelizon, P. Romanowski, A.D. Mills & R.A. Laskey: The roles of the MCM, ORC, and Cdc6 proteins in determining the replication competence of chromatin in quiescent cells. J Struc Biol 129, 198-210 (2000)
87. Coverley D, H. Laman & R.A. Laskey: Distinct roles for cyclins E and A during DNA replication complex assembly and activation. Nat Cell Biol 4, 523-8 (2002)
88. Matsumoto Y & J.L. Maller: A centrosomal localization signal in cyclin E is required for Cdk2-independent S phase entry. Nature 306, 885-8 (2004)
89. Geisen G and T. Möröy: The oncogenic activity of cyclin E is not confined to Cdk2 activation alone but relies on several other, distinct functions of the protein. J Biol Chem 277, 39909-18 (2002)
90. Sweeney C, M. Murphy, M. Kubelka, S.E. Ravnik, C.F. Hawkins, D.J. Wolgemuth & M. Carrington: A distinct cyclin A is expressed in germ cells in the mouse. Development 122, 53-64 (1996)
91. Ji P, S. Agrawal, S. Diederichs, N. Bäumer, A. Becker, T. Cauvet, S. Kowski, C. Beger, K. Welte, W.E. Berdel, H. Serve & C. Müller-Tidow: Cyclin A1, the alternative A-type cyclin, contributes to G1/S cell cycle progression in somatic cells. Oncogens 24, 2739-44 (2005)
92. Murphy M, M.G. Stinnakre, C. Senamaud-Beaufort, N.J. Winston, C. Sweeney, M. Kubelka, M. Carrington, C. Brechot & J. Sobzack-Thepot: Delayed early embryonic lethality following disruption of the murine cyclin A2 gene. Nat Genet 15, 83-86 (1997)
93. Furuno N, N. den Elzen & J. Pines: Human cyclin A is required for mitosis until mid prophase. J Cell Sci 147, 295-306 (1999)
94. Clute P & J. Pines: Temporal and spatial control of Cyclin B1 destruction in metaphase. Nat Cell Biol 1, 82-7 (1999)
95. Draviam VM, S. Orrechia, M. Lowe, R. Pardi & J. Pines: The localization of human cyclins B1 and B2 determines CDK1 substrate specificity and neither enzyme requires MEK to disassemble the Golgi apparatus. J Cell Biol 152, 945-58 (2001)
96. Brandeis M, I. Rosewell, M. Carrington, T. Crompton, M.A. Jacobs, J. Kirk, J. Gannon & T. Hunt: Cyclin B2-null mice develop normally and are fertile whereas cyclin B1-null mice die in utero. Proc Natl Acad Sci USA 95, 4344-9 (1998)
97. Nguyen TB, K. Manova, P. Capodieci, C. Lindon, S. Bottega, X.Y. Wang, J. Refik-Rogers, J. Pines, D. Wolgemuth & A. Koff: Characterization and expression of mammalian Cyclin B3, a prepachytene meiotic cyclin. J Biol Chem 277, 41960-9 (2002)
98. Malumbres M & M. Barbacid: To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 1, 222-31 (2001)
99. Deshpande A, P. Sicinski & P.W. Hinds: Cyclins and cdks in development and cancer: a perspective. Oncogene 24, 2909-15 (2005)
100. Wang TC, R.D. Cardiff, L. Zukergerg, E. Lees, A. Arnold & E.V. Schmidt: Mammary hyperplasia and carcinoma in MMTV-Cyclin D1 transgenic mice. Nature 369, 669-71 (1994)
101. Kong G, S.S. Chua, Y. Yijun, F. Kittrell, R.C. Moraes, D. Medina & T.K. Said: Functional analysis of cyclin D2 and p27Kip1 in cyclin D2 transgenic mouse mammary gland during development. Oncogene 21, 7214-25 (2002)
102. Bodrug SE, B.J. Warner, M.L. Bath, G.J. Lindeman, A.W. Harris & J.M. Adams: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13, 2124-30 (1994)
103. Soonpaa MH, G.Y. Koh, L. Pajak, S. Jing, H. Wang, M.T. Franklin, K.K. Kim & L.J. Field: Cyclin D1 overexpression promotes cardyomyocite DNA synthesis and multinucleation in transgenic mice. J Clin Invest 99, 2644-54 (1997)
104. Gómez LaHoz E, N.J. Liegeois, P. Zhang, J.A. Engelman, J. Horner, A. Silverman, R. Burde, M.F. Roussel, C.J. Sherr, S.J. Elledge and R. DePinho: CyclinD- and E- dependent kinases and the p57Kip2 inhibitor: cooperative interactions in vivo. Mol Cell Biol 19, 353-63 (1999)
105. Ortega S, M. Malumbres & M. Barbacid: Cell Cycle and cancer: the G1 restriction point and the G1/S transition. Current Genomics 3, 245-263 (2002)
106. Miliani de Marval P, I. Giménez-Conti, M. La Cava, L. Martínez, C. Conti & M. Rodríguez-Puebla: Transgenic expression of Cyclin-dependent kinase 4 results in epidermal hiperplasya, hipertrophy and severe dermal fibiosis. Am J Pathol 159, 369-79 (2001)
107. Rodríguez-Puebla ML, M. LaCava & C. Conti: Cyclin D1 overexpression in mouse epidermis increases Cyclin-dependent kinase activity and cell proliferation in vivo but does not affect skin tumor development. Cell Growth Diff 10, 467-472 (1999)
108. Keyomarsi K & A.B. Pardee: Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci USA 90, 1112-16 (1993)
109. Porter DC, N. Zhang, C. Danes, M.J. McGrehan, R.M. Harwell, S. Faruki & K. Keyomarsi: Tumor-specific proteolytic processing of Cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21, 6254-69 (2001)
110. Wingate H, N. Zhang, M.J. McGarhen, I. Bedrosian, J.W. Harper & K. Keyomarsi: The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280, 15148-57 (2005)
111. Keyomarsi K, S.L. Tucker, T.A. Buchholz, M. Callister, Y. Ding, I. Bedrosian, G.N. Hortobagyi, C. Knickerbucker, W. Toyofuku, M. Lowe, T.W. Herliczec & S.S. Bacus: Cyclin E and survival in patients with breast cancer. New England J Med 347, 1566-75 (2002)
112. Bortner DM & M.P. Rosenberg: Induction of mammary gland hyperplasia and carcinomas in transgenic mice expressing human Cyclin E. Mol Cell Biol 17, 453-59 (1997)
113. Zwijsen RM, E. Wientjens, R. Klompmaker, J. van der Sman, R. Bernards & R.J. Michaelide: CDK-independent activation of estrogen receptor by Cyclin D1. Cell 88, 405-15 (1997)
114. Karsunky H, C. Geisen, T. Schmidt, K. Haas, B. Zevnik, E. Gau et al.: Oncogenic potential of Cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for the cooperation between Cyclin E and Ras but not Myc. Oncogens 18, 7816-24 (1999)
115. Geisen C, H. Karsunky, R. Yucel & T. Möröy: Loss of p27(kip1) cooperates with Cyclin E in T-cell lymphomagenesis. Oncogene 22, 1724-29 (2003)
116. Bortner DM & M.P. Rosenberg: Overexpression of cyclin A in the mammary glands of transgenic mice results in the induction of nuclear abnormalities and increased apoptosis. Cell Growth Differ 6, 1579-89 (1995)
117. Ruas M & G. Peters: The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1378, F115-77 (1998)
118. Wolfel T, M. Hauer, J. Schneider, M. Serrano, C. Wolfel, E. Klehmann-Hieb, E. De Plaen, T. Hankeln, K.H. Buschenfelde & D. Beach: A p16INK4a-insensitive Cdk4 mutant targeted by cytolitic lymphocytes in a human melanoma. Science 269, 1281-4 (1995)
119. Zuo L, J. Weger, Q. Yang, A.M. Goldstein, M.A. Tucker, G.J. Walker, N. Hayward & N.C. Dracopoli: Germline mutations in the p16INK4a binding domain of Cdk4 in familial melanoma. Nat Genet 12, 97-9 (1996)
120. R24C mutation facilitates tumorigenesis and escape from cellular senescence. Mol Cell Biol 22, 644-56 (2002)
121. Sotillo R, J.F. Garcia, S. Ortega, J. Martin, P. Dubus, M. Barbacid & M. Malumbres: Invasive melanoma in Cdk4 targeted mice. Proc Natl Acad Sci USA 98, 13312-7 (2001)
122. nd, C. Cordón-Cardo, G.D. Yancopoulos & R.A. DePinho: Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468-72 (1999)
123. Lloyd RV, L.A. Erickson, L. Jin, E. Kulig, X. Qian, J.C. Cheville & B.W. Scheithauer: p27Kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154, 313-23 (1999)
124. Tsihlias J, L. Kapusta & J. Slingerland: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Anna Rev Med 50, 401-23 (1999)
125. Zou X, D. Ray, A. Aziyu, K. Christov, A.D. Boiko, A.V. Gudkov & H. Kiyokawa: Cdk4 disruption renders primary mouse cells resistant to oncogenic transformation, leading to Arf/p53-independent senescence. Genes Dev 16, 2923-34 (2002)
126. Hulit J, C. Wang, Z. Li, C. Albanese, M. Rao, D. Di Vizio, S. Shah, S.E.W. Byers, R. Mahmood, L.H. Augenlicht, R. Russell & R.G. Pestell: Cyclin D1 genetic heterozygosity regulates colonic epithelial cell differentiation and tumor number in ApcMin mice. Mol Cell Biol 24, 7598-611 (2004)
127. Robles AI, M.L. Rodríguez-Puebla, A.B. Glick, C. Trempus, L. Hansen, P. Sicinski, R.W. Tennant, R.A. Weinberg, S.H. Yuspa & C.J. Conti: Reduced skin tumor development in Cyclin-D1 deficient mice highlights the oncogenic ras pathway in vivo. Genes Dev 12, 2469-74 (1998)
128. Yu Q & P. Sicinski: Specific protection against breast cancers by cyclin D1 ablation. Nature 411, 1017-21 (2001)
129. Burns KH, J.E. Agno, P. Sicinski & M.M. Matzuk: Cyclin D2 and p27 are tissue-specific regulators of tumorigenesis in inhibin alpha knockout mice. Mol Endocrinol 10, 2053-69 (2003)
130. Sicinska E, I. Aifantis, L. Le Cam, W. Swat, C. Borowski, Q. Yu, A. Ferrando, S.D. Levin, Y. Geng, H. von Boehmer & P. Sicinski: Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell 4, 451-61 (2003)
131. Rodríguez-Puebla ML, P.L. Miliani de Marval, M. LaCava, D.S. Moons, H. Kiyokawa & C.J. Conti: Cdk4 deficiency inhibits skin tumor development but does not affect keratynocite proliferation. Am J Pathol 161, 405-11 (2002)
132. Miliani de Marval PL, E. Macias, R. Rounbehler, P. Sicinski, H. Kiyokawa, D.G. Johnson, C.J. Conti & M.L. Rodríguez-Puebla: Lack of Cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 24, 7538-47 (2004)
133. Martín A, J. Odajima, S.L. Hunt, P. Dubus, S. Ortega, M. Malumbres, & M. Barbacid: Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27Kip1 and p21Cip1. Cancer Cell 7, 1-8 (2005)
134. Toyoshima H & T. Hunter: p27, a novel inhibitor of G1 cyclin-cdk protein kinase activity, is related to p21. Cell 78, 67-74 (1994)
135. Harper JW, S.J. Elledge, K. Keyomarsi, B. Dynlacht, L.H. Tsai, P. Zhang, S. Dobrowolski, C. Bai, L. Connell-Crowley, E. Swindell et al.: Inhibition of Cyclin-dependent kinases by p21. Mol Biol Cell 6, 387-400 (1995)
136. Bernards R: CDK-independent activities of D type cyclins. Biochim Biophys Acta 1424, M17-22 (1999)
137. Ewen ME & J. Lamb: The activities of cyclin D1 that drive tumorigenesis. TRENDS Mol Med 10, 158-62 (2004)
138. Kim HA, S.L. Pomeroy, W. Whoriskey, I. Pawlitzky, L.I. Benowitz, P. Sicinski, C.D. Stiles & T.M. Roberts: A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. Neuron 26, 405-16 (2000)
139. Atanasoski S, S. Shumas, C. Dickson, S.S. Scherer & U. Suter: Differential cyclin D1 requirements of proliferating Schwann cells during development and after injury. Mol Cell Neurosci 18, 581-92 (2001)
140. Huard JM, C.C. Foster, M.L. Carter, P. Sicinski & M.E. Ross: Cerebellar histogenesis is disturbed in mice lacking cyclin D2. Development 126, 1927-35 (1999)
141. Lam EW, J. Glassford, L. Banerji, N.S. Thomas, P. Sicinski & G.G. Klaus: Cyclin D3 compensates for loss of cyclin D2 in mouse B-lymphocytes activated via the antigen receptor and CD40. J Biol Chem 275, 3479-84 (2000)
142. Solvason N, W.W. Wu, D. Parry, D. Mahony, E.W. Lam, J. Glassford, G.G. Klaus, P. Sicinski, R. Weinberg, Y.J. Liu, M. Howard & E. Lees: Cyclin D2 is essential for BCR-mediated proliferation and CDS B cell development. Int Immunol 12, 631-8 (2000)
143. Kowalczyk A, R.K. Filipkowski, M. Rylski, G.M. Wilczynski, F.A. Jaworski, M.A. Ciemerych, P. Sicinski & L. Kaczmarek: The critical role of cyclin D2 in adult neurogenesis. J Cell Biol 167, 209-13, (2004)
144. Krimpenfort P, K.C. Quon, W.J. Mooi, A. Loonstra & A. Berns: Loss of p16Ink4a confers susceptibility to metastatic melanoma in mice. Nature 413, 83-6 (2001)
145. Sharpless NE, N. Bardeesy, K.H. Lee, D. Carrasco, D.H. Castrillon, A.J. Aguirre, E.A. Wu, J.W. Horner & R.A. DePinho: Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature 413, 86-91 (2001)
146. Latres E, M. Malumbres, R. Sotillo, J. Martin, S. Ortega, J. Martin-Caballero, J.M. Flores, C. Cordón-Cardo & M. Barbacid: Limited overlapping roles of p15INK4b and p18INK4c cell cycle inhibitors in proliferation and tumorigenesis. EMBO J 19, 3496-506 (2000)
147. Franklin DS, V.L. Godfrey, H. Lee, G.I. Kovalev, R. Schoonhoven, S. Chen-Kiang, L. Su & Y. Xiong: Cdk inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12, 2899-911 (1998)
148. Zindy F, W. den Besten, B. Chen, J.E. Reg, E. Latres, M. Barbacid, J.W. Pollard, C.J. Sherr, P.E. Cohen & M.F. Roussel: Control of spermatogenesis in mice by the Cyclin D-dependent kinase inhibitors p18 (Ink4c) and p19 (Ink4d). Mol Cell Biol 21, 3244-55 (2001)
149. Bai F, X.H. Pei, V.L. Godfrey & Y. Xiong: Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis. Mol Cell Biol 23, 1269-77 (2003)
150. Zindy F, J. van Deursen, G. Grosveld, C.J. Sherr & M.F. Roussel: INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 20, 372-8 (2000)
151. Chen P, F. Zindy, C. Abdala, F. Liu, X. Li, M.F. Roussel & N. Segil: Progressive hearing loss in mice lacking the cyclin-dependent kinase inhibitor Ink4d. Nat Cell Biol 5, 385-7 (2003)
152. Serrano M, H.-W. Lee., L. Chin, C. Cordon-Cardo, D. Beach & R.A. DePinho: Role of the INK4a locus in tumor supression. Cell 85, 27-37 (1996)
153. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82, 675-84 (1995)
154. Brugarolas J, C. Chandrasekaran, J.I. Gordon, D. Beach, T. Jacks. & G.J. Hannon: Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature 377, 552-7 (1995)
155. Waf1/Cip1-deficient mice. Cancer Res 61, 6234-38 (2001)
156. WAF1/CIP1 enhances Apc-initiated tumor formation and the tumor-promoting activity of a Western-style high-risk diet by altering cell maturation in the intestinal mucosa. Cancer Res 61, 565-9 (2001)
157. Brugarolas J, R.T. Bronson & T. Jacks: p21 is a critical CDK2 regulator essential for proliferation control in Rb-deficient cells. J Cell Biol 141, 503-14 (1998)
158. WAF1/CIP1 accelerates Ras oncogenesis in a transgenic/knockout mammary cancer model. Oncogene 19, 5338-47 (2000)
159. Bearss DJ, R.J. Lee, D.A. Troyer, R.G. Pestell & J.J. Windle: Differential effects of p21(WAF1/CIP1) deficiency on MMTV-ras and MMTV-myc mammary tumor properties. Cancer Res 62, 2077-84 (2002)
160. Yang WC, J. Mathew, A. Velcich, W. Edelmann, R. Kucherlapati, M. Lipkin, Y.A. Wang, A. Elson & P. Leder: Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. Proc Natl Acad Sci USA 94, 14590-5 (1997)
161. Fotedar R, H. Brickner, N. Saadatmandi, T. Rousselle, L. Diederich, A. Munshi, B. Jung, J.C. Reed & A. Fotedar: Effect of p21waf1/cip1 transgene on radiation induced apoptosis in T cells. Oncogene 18, 3652-8 (1999)
162. Kiyokawa H, R.D. Kineman, K.O. Manova-Todorova, V.C. Soares, E.S. Hoffamn, M. Ono, D. Khanam, A.C. Hayday, L.A. Forman & A. Koff: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27Kip1. Cell 85, 721-32 (1996)
163. Nakayama K, N. Ishida, M. Shirane, A. Inomata, T. Inoue, N. Shishido, I. Horii & D. Y. Loh: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 85, 707-20 (1996)
164. Fero ML, -M. Rivkin, M. Tasch, P. Porter, C.E. Carow, E. Firpo, K. Polyak, L.H. Tsai, V. Broudy, R.M. Perlmutter, K. Kaushansky & J.M. Roberts: A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and females esterility in p27Kip1-deficient mice. Cell 85, 733-744 (1996)
165. Kip1 is haplo-insufficient for tumour supresion. Nature 396, 177-80 (1998)
166. Muraoka RS, A.E. Lenferink, B. Law, E. Hamilton, D.M. Brantley, L.R. Roebuck & C.L. Arteaga: ErbB2/Neu-induced, Cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol 22, 2204-19 (2002)
167. Geisen C, H. Karsunky, R. Yucel & T. Moroy: Loos of p27Kip1 cooperates with Cyclin E in T-cell lymphomagenesis. Oncogene 22, 1724-9 (2003)
168. Martin-Caballero J, J.M. Flores, P. García-Palencia, M. Collado & M. Serrano: Different cooperating effect of p21 or p27 deficiency in combination with INK4a/ARF deletion in mice. Oncogene 23, 8231-7 (2004)
169. Martins CP & A. Berns: Loss of p27(Kip1) but not p21(Cip1) decreases survival and synergizes with MYC in murine lymphomagenesis. EMBO J 21, 3739-48 (2002)
170. Yan Y, J. Frisen, M.H. Lee, J. Massagué & M. Barbacid: Ablation of the Cdk inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development. Genes Dev 11, 973-83 (1997)
171. Zhang P, N. Liégeois, C. Wong, M. Finegold, H. Hou, J.C. Thompson, A. Silverman, J.W. Harper, R.A. DePinho & S.J. Elledge: Altered cell differentiation and proliferation in mice lacking p57KIP2 indicates a role in Beckwith-Wiedemann sindrome. Nature 387, 151-158 (1997)
172. Jirawatnotai S, D.S. Moons, C.O. Stocco, R. Franks, D.B. Hales, G. Gibori & H. Kiyokawa: The cyclin-dependent kinase inhibitors p27Kip1 and p21Cip1 cooperate to restrict proliferative life span in differentiating ovarian cells. J Biol Chem 278, 17021-7 (2003)
173. Wolfraim LA, T.M. Walz, Z. James, T. Fernàndez & J. Letterio: p21Cip1 and p27Kip1 act in synergy to alter the sensitivity of naïve T cells to TGF-beta-mediated G1 arrest through modulation of IL-2 responsiveness. J Immunol 3093-102 (2004)
174. Kip2 control muscle differentiation at the myogenin step. Genes Dev 13, 213-24 (1999)
175. Kip2 in the control of tissue growth and development. Genes Dev 12, 3162-7 (1998)
176. Franklin DS, V.L. Godfrey, D.A. O'Brien, C. Deng, & Y. Xiong: Functional collaboration between different cyclin-dependent kinase inhibitors suppresses tumor growth with distinct tissue specificity. Mol Cell Biol 20, 6147-58 (2000)
177. Zindy F, J.J. Cunningham, C.J. Sherr, S. Jogal, R.J. Smeyne & M.F. Roussel: Postnatal neuronal proliferation in mice lacking Ink4d and Kip1 inhibitors of cyclin-dependent kinases. Proc Natl Acad Sci USA 96, 13462-7 (1999)
178. Pei XH, F. Bai, T. Tsutsui, H. Kiyokawa & Y. Xiong: Genetic evidence for functional dependency of p18Ink4c on Cdk4. Mol Cell Biol 24, 6653-64 (2004)
179. Sotillo R, O. Renner, P. Dubus, J. Ruiz-Cabello, J. Martin-Caballero, M. Barbacid, A. Carnero & M. Malumbres: Cooperation between Cdk4 and p27Kip1 in tumor development: a preclinical model to evaluate cell cycle inhibitors with therapeutic activity. Cancer Res 65, 3846-52 (2005)
180. Tong W & J.W. Pollard: Genetic evidence for the interactions of Cyclin D1 and p27 (Kip1) in mice. Mol Cell Biol 21, 1319-28 (2001)